Reference19 articles.
1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1;Rajkumar;Blood,2011
2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021
3. Updated results from CARTITUDE-1: phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma;Martin;Blood,2021
4. Ide-cel or standard regimens in relapsed and refractory multiple myeloma;Rodriguez-Otero;N Engl J Med,2023
5. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma;San-Miguel;N Engl J Med,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiple drugs;Reactions Weekly;2024-08-10